Drugs / Topiroxostat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02837198 | Jul 2016 → Aug 2017 | — | Fuji Yakuhin Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02327754 Comparator | ? → Dec 2016 | diabetic kidney disease | Sanwa Kagaku Kenkyusho Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Topiroxostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02327754 ↗ |
| Known as | FYX-051 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078685 ↗ |
| Action | Inhibit | “Xanthine dehydrogenase inhibitor” CHEMBL1078685 ↗ |
| Modality | Small molecule | — CHEMBL1078685 ↗ |
| Route | Oral | “Oral daily dosing for 28 weeks” NCT02327754 ↗ |
| Target | XDH | “Xanthine dehydrogenase inhibitor” CHEMBL1078685 ↗ |